Einloggen

Thematische Bibliographien / Ovarian paraganglioma / Zeitschriftenartikel

Um die anderen Arten von Veröffentlichungen zu diesem Thema anzuzeigen, folgen Sie diesem Link: Ovarian paraganglioma.

Zeitschriftenartikel zum Thema „Ovarian paraganglioma“

Autor: Grafiati

Veröffentlicht am 7. Juni 2025

Zuletzt aktualisiert am 2. August 2025

Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an

Wählen Sie eine Art der Quelle aus:

Machen Sie sich mit Top-32 Zeitschriftenartikel für die Forschung zum Thema "Ovarian paraganglioma" bekannt.

Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.

Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.

Sehen Sie die Zeitschriftenartikel für verschiedene Spezialgebieten durch und erstellen Sie Ihre Bibliographie auf korrekte Weise.

1

ETTAOUSSI, Abdelhak, Khalid JAMALEDDINE, Abdessamad MAJD, et al. "Incidental Ovarian Paraganglioma in a 62-Year-Old Woman: A Case Report of Diagnostic Challenge and Surgical Management." INTERNATIONAL JOURNAL OF HEALTH & MEDICAL RESEARCH 04, no. 03 (2025): 143–47. https://doi.org/10.5281/zenodo.15030718.

Der volle Inhalt der Quelle

Annotation:

Paragangliomas are rare neuroendocrine tumors originating from chromaffin cells of the neural crest. While they typically occur in the adrenal medulla as pheochromocytomas or along the sympathetic and parasympathetic chains, paragangliomas in the female genital tract are exceptionally uncommon. This report presents a case of a large right ovarian paraganglioma in a 62-year-old woman with a medical history of hypertension and diabetes. She presented with abdominal pain and fever, which led to a diagnosis of appendicitis, though an unexpected adnexal mass was discovered during surgery. Histologi

APA, Harvard, Vancouver, ISO und andere Zitierweisen

2

Pedroso, Célia, Raquel Robalo, Pedro Sereno, Carlos Barros, and Carlos Marques. "A Rare Abdomino-Pelvic Tumor: Paraganglioma." Acta Médica Portuguesa 28, no. 1 (2015): 114. http://dx.doi.org/10.20344/amp.5403.

Der volle Inhalt der Quelle

Annotation:

<p>Paragangliomas are rare tumors, with a reported incidence of 2–8 per million. They are chromaffin cell tumors that develop from the neural crest cells and may be divided in tumors derived from the parasympathetic or sympathetic ganglia. We report a case a of a 32-year-old nulliparous woman, referred to our Infertility Clinic. Abdomino-pelvic ultrasound identified a large abdominopelvic tumor, without ovarian origin (both ovaries were identified and had normal morphology). Magnetic Resonance Imaging suggested a right adnexal multicystic, vascularized mass close to iliac vessels and que

APA, Harvard, Vancouver, ISO und andere Zitierweisen

3

Schuldt, Maolly, Juan Antonio Retamero, Malvina Tourné, and Francisco F. Nogales. "Ovarian Paraganglioma." International Journal of Surgical Pathology 23, no. 2 (2014): 130–33. http://dx.doi.org/10.1177/1066896914526779.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

4

Kumar, Manish, Aashima Dabas, Vivek Manchanda, Nidhi Mahajan, and Kaustuv Mitra. "Hyponatremic-Hypertensive Syndrome in Ovarian Paraganglioma." Indian Pediatrics 56, no. 1 (2019): 69–71. http://dx.doi.org/10.1007/s13312-019-1472-z.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

5

Elliot, Victoria J., Emily C. Shaw, Mark Walker, Eleanor Jaynes, and Jeffery M. Theaker. "Ovarian Paraganglioma Arising From Mature Cystic Teratoma." International Journal of Gynecological Pathology 31, no. 6 (2012): 545–46. http://dx.doi.org/10.1097/pgp.0b013e31824d3564.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

6

Alli, Kasumawati, Basri Johan Jeet Abdullah, Collin Ng Leong Liong, and Eugene Leong Weng Kong. "Left retroperitoneal paraganglioma with enlarged ovarian vessels." European Journal of Radiology Extra 67, no. 1 (2008): 29–32. http://dx.doi.org/10.1016/j.ejrex.2008.04.011.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

7

Lim, Eng Seng, Hwee Ching Tee, and Jin Hui Ho. "UNVEILING THE UNEXPECTED." Journal of the ASEAN Federation of Endocrine Societies 40, S1 (2025): 97–98. https://doi.org/10.15605/jafes.040.s1.166.

Der volle Inhalt der Quelle

Annotation:

INTRODUCTION/BACKGROUNDParagangliomas are rare neuroendocrine tumors that arise from extra-adrenal paraganglionic tissue, typically associated with the autonomic nervous system. While they are most commonly found in the adrenal medulla (as pheochromocytomas) or along the sympathetic and parasympathetic chains, their occurrence in the paraovarian region is extremely rare. CASEWe present the case of a 42-year-old female with a history of left external iliac and common femoral vein thrombosis, who presented with progressive abdominal distension over the past six months. She was normotensive and e

APA, Harvard, Vancouver, ISO und andere Zitierweisen

8

Chishima, Fumihisa, Masaaki Tamura, Teine Nakazawa, et al. "Paraaortic paraganglioma arising in an ovarian carcinoma patient mimicking lymph node metastasis." Journal of Obstetrics and Gynaecology Research 36, no. 1 (2010): 204–8. http://dx.doi.org/10.1111/j.1447-0756.2009.01094.x.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

9

Sahin, Gozde, Ceyhan Ugurluoglu, Serra Akar, Ayhan Gul, Aysegul Kebapcilar, and Cetin Celik. "Para-aortic paraganglioma mimicking lymph node metastasis in an ovarian carcinoma: a case report." Journal of Obstetrics and Gynaecology 38, no. 6 (2018): 882–84. http://dx.doi.org/10.1080/01443615.2017.1404013.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

10

Bizzarri, Nicolò, Franco De Cian, Stefano Di Domenico, et al. "Peritoneal carcinomatosis from ovarian paraganglioma: Report of a rare case and systematic review of the literature." Journal of Obstetrics and Gynaecology Research 44, no. 9 (2018): 1682–92. http://dx.doi.org/10.1111/jog.13713.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

11

Elbaset, M. A., Abdelwahab Hashem, M. Abd Elhameed, and Ahmed S. El-Hefnawy. "Concomitant primary ovarian paraganglioma neuroendocrinal differentiated urothelial tumor in a BOTOX-injected bladder: A case report." International Journal of Surgery Case Reports 57 (2019): 122–25. http://dx.doi.org/10.1016/j.ijscr.2019.03.026.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

12

Yang, Shan, Scott T. Michalski, Jennifer Holle, et al. "Unexpected germline mutations in a pan-cancer analysis including sarcoma, renal, and other cancers." Journal of Clinical Oncology 35, no. 15_suppl (2017): 1584. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.1584.

Der volle Inhalt der Quelle

Annotation:

1584 Background: Multi-gene testing for cancer predisposition is increasingly utilized in clinical care. Although the diagnostic yield and management implications of such testing in breast, ovarian and colorectal cancer are relatively well understood, data for other cancer types are still emerging. In this study we retrospectively examined 39,147 patients referred for hereditary cancer syndrome testing for pathogenic germline variants in 80 cancer risk genes, focusing on those patients with renal, sarcoma, paraganglioma, melanoma, and pancreatic cancers. Methods: Test results and personal/fami

APA, Harvard, Vancouver, ISO und andere Zitierweisen

13

Ajluni, Steven, Elizabeth Jean-Marie, Rafey Feroze, Carl Barton Gillombardo, and Varun Sundaram. "PARAGANGLIOMA-INDUCED REVERSE TAKOTSUBO CARDIOMYOPATHY TREATED WITH EXTRACORPOREAL MEMBRANE OXYGENATION IN A PATIENT WITH PRIMARY OVARIAN INSUFFICIENCY: A CASE REPORT." Journal of the American College of Cardiology 81, no. 8 (2023): 3197. http://dx.doi.org/10.1016/s0735-1097(23)03641-0.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

14

Reyna-Villasmil, Eduardo, Duly Torres-Cepeda, and Martha Rondon-Tapia. "Paraganglioma vulvovaginal primario. Reporte de caso." Revista Peruana de Ginecología y Obstetricia 65, no. 4 (2019): 549–53. http://dx.doi.org/10.31403/rpgo.v65i2215.

Der volle Inhalt der Quelle

Annotation:

El paraganglioma es una neoplasia neuroendocrina extraadrenal derivada de precursores de la cresta neural, que surgen en asociación con los ganglios autónomos y, en ocasiones, también son denominados feocromocitomas extraadrenales. Se definen por su sitio anatómico y si son o no hormonalmente funcionales. Los paragangliomas son neoplasias poco frecuentes del tracto genital femenino y pueden aparecer en ovarios, útero o cuello uterino. Los que aparecen en la región vulvovaginal son extremadamente raros. Las manifestaciones clínicas dependen de la secreción no regulada de catecolaminas y la loca

APA, Harvard, Vancouver, ISO und andere Zitierweisen

15

Al-ward, Ruaa. "OR29-3 High-specific-activity Iodine 131 Metaiodobenzylguanidine for the Treatment of Advanced Pheochromocytoma and Paraganglioma: A Real-world Study." Journal of the Endocrine Society 6, Supplement_1 (2022): A880—A881. http://dx.doi.org/10.1210/jendso/bvac150.1823.

Der volle Inhalt der Quelle

Annotation:

Abstract Introduction Metastatic pheochromocytomas/paragangliomas (mPPGLs) are rare tumors with limited treatment options. High-specific-activity 131I-meta-iodobenzylguanidine (HSA 131I-MIBG) is the only approved therapy for mPPGLs. We summarized the efficacy and safety profile of HSA 131I-MIBG in patients with mPPGL. Methods This is a retrospective cohort study in patients with mPPGL treated with HSA 131I-MIBG on label at a tertiary cancer center. The primary endpoint was radiographic treatment response determined with CT/MRI according to RECIST v1.1 and 123 I-MIBG scan. Secondary endpoints w

APA, Harvard, Vancouver, ISO und andere Zitierweisen

16

Gribbin, T. E., N. Senzer, J. J. Raizer, et al. "A phase I evaluation of intravenous (IV) 131I-chlorotoxin delivery to solid peripheral and intracranial tumors." Journal of Clinical Oncology 27, no. 15_suppl (2009): e14507-e14507. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e14507.

Der volle Inhalt der Quelle

Annotation:

e14507 Background: Pre-clinical studies demonstrate TM601 binding to glioblastoma, melanoma, and other tumor types in vitro and in vivo (human xenograft tumors in mice). Here we report imaging and safety data from a Phase I clinical trial in patients with recurrent metastatic somatic and/or cerebral solid tumors that received IV 131I-TM601. Methods: Patients received an IV imaging test dose of 10 mCi/0.2mg 131I-TM601. Subjects not showing tumor localization, received a second imaging test dose of 20 mC/0.4mg 131I-TM601. Subjects without localization at either dose were dropped from study; pati

APA, Harvard, Vancouver, ISO und andere Zitierweisen

17

Saavedra Santa Gadea, Omar, Alberto Hernando-Calvo, Roger Berche, et al. "Evaluating the role of immune-checkpoint inhibitor (ICI) combinations in patients (pts) with unselected “cold” tumors enrolled in early clinical trials (CT)." Journal of Clinical Oncology 39, no. 15_suppl (2021): 2597. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.2597.

Der volle Inhalt der Quelle

Annotation:

2597 Background: In order to improve the expected response rate (ORR) of less than 10% in cold tumors, several ICI combinations are being evaluated in clinical trials. However, most of these trials don’t require any biomarker and pts are included based solely in histology. We aimed to assess the benefit of ICI combinations in pts with unselected cold tumors included in early CT. Methods: ICI naïve pts with cold tumors treated from 2015 to 2021 with ICI combinations in early CT at VHIO were reviewed. Clinico-pathological data and anti-tumor activity were extracted from a prospective database. O

APA, Harvard, Vancouver, ISO und andere Zitierweisen

18

Chiba, Akiko, Andrea Stoddard, Wendy Kohlmann, et al. "Outcomes of germline expedited point of care (POC) genetic testing through telehealth in the Veterans Health Administration (VA)." Journal of Clinical Oncology 43, no. 16_suppl (2025): 1655. https://doi.org/10.1200/jco.2025.43.16_suppl.1655.

Der volle Inhalt der Quelle

Annotation:

1655 Background: Germline genetic testing is standard of care for treatment planning for several malignancies. To increase access to genetic testing for Veterans, VA developed and disseminated educational materials, laboratory portal access, and templates for ordering and documenting consent and testing in the electronic health record to facilitate POC testing by oncology providers. Here, we describe the outcomes of POC testing. Methods: POC tests ordered between 2/24/23-11/18/24 by oncology providers at VA sites or with National TeleOncology (NTO) were identified through the VHA’s Corporate D

APA, Harvard, Vancouver, ISO und andere Zitierweisen

19

Solarski, Michael, Fabio Rotondo, William D. Foulkes, et al. "DICER1 gene mutations in endocrine tumors." Endocrine-Related Cancer 25, no. 3 (2018): R197—R208. http://dx.doi.org/10.1530/erc-17-0509.

Der volle Inhalt der Quelle

Annotation:

In this review, the importance of theDICER1gene in the function of endocrine cells is discussed. There is conclusive evidence thatDICER1mutations play a crucial role in the development, progression, cell proliferation, therapeutic responsiveness and behavior of several endocrine tumors. We review the literature ofDICER1gene mutations in thyroid, parathyroid, pituitary, pineal gland, endocrine pancreas, paragangliomas, medullary, adrenocortical, ovarian and testicular tumors. Although significant progress has been made during the last few years, much more work is needed to fully understand the

APA, Harvard, Vancouver, ISO und andere Zitierweisen

20

Victoria, Iván, Debora Moreno Fernandez, Laura Angelats, et al. "Genetic profiling across multiple cancer types using molecular prescreening comprehensive gene panels offered by clinical trials (CT)." Journal of Clinical Oncology 39, no. 15_suppl (2021): 3060. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.3060.

Der volle Inhalt der Quelle

Annotation:

3060 Background: Genetic profiling (GP) is essential not only for understanding tumor biology but also helps to identify potential genes for targeted therapies. At the same time, selected CT provide an individual genomic profile panel during the pre-screening phase. Here, we demonstrate our experience using these panels. Methods: We selected 14 CT from our Early Drug Development Clinical Trial Unit at Hospital Clinic of Barcelona that included analysis of gene panels in tumor (Foundation One, ArcherDX, Therascreen and Sophia Genetics) or plasma (Resolution Bioscience ctDx). These panels analyz

APA, Harvard, Vancouver, ISO und andere Zitierweisen

21

Viehweger, Florian, David Dum, Anne Menz, et al. "Abstract 2164: Patterns of estrogen receptor expression across 18,500 tumor samples obtained from 149 cancer types." Cancer Research 83, no. 7_Supplement (2023): 2164. http://dx.doi.org/10.1158/1538-7445.am2023-2164.

Der volle Inhalt der Quelle

Annotation:

Abstract Estrogen receptor alpha (ER) is a nuclear transcription factor with a pivotal role in the function of the reproductive organs and of other organ systems. It constitutes a well-established therapeutic target for various small molecules. ER immunohistochemistry is used in surgical pathology for the distinction of tumors of the breast and gynecological organs. To comprehensively determine ER expression in normal and neoplastic tissues, a tissue microarray containing 18,560 samples from 149 different tumor types and subtypes as well as 608 samples of 76 different normal tissue types was a

APA, Harvard, Vancouver, ISO und andere Zitierweisen

22

Maroto, Pablo, Camillo Porta, Jaume Capdevila, et al. "Cabozantinib for the treatment of solid tumors: a systematic review." Therapeutic Advances in Medical Oncology 14 (January 2022): 175883592211071. http://dx.doi.org/10.1177/17588359221107112.

Der volle Inhalt der Quelle

Annotation:

Background: Cabozantinib is approved, in various settings, for the treatment of renal cell carcinoma, medullary thyroid cancer, and hepatocellular carcinoma, and it has been investigated for the treatment of other cancers. With the available evidence and the real-world performance of cabozantinib compared with clinical trial data, we performed a systematic review of cabozantinib monotherapy as treatment for solid tumors in adults. Methods: This study was designed in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses and registered with PROSPERO (CRD42020144680).

APA, Harvard, Vancouver, ISO und andere Zitierweisen

23

Д.В., Васендин. "Nuclear melatonin receptors." Zhurnal «Patologicheskaia fiziologiia i eksperimental`naia terapiia» 68, no. 2 (2024): 87–96. http://dx.doi.org/10.25557/0031-2991.2024.02.87-96.

Der volle Inhalt der Quelle

Annotation:

Мелатонин – гормон, продуцируемый в центральной нервной системе (эпифизе) и периферических тканях (аппендиксе, поджелудочной железе, надпочечниках, тимусе, простате, яичниках, плаценте). Его секретируют клетки крови (тромбоциты, лимфоциты и эозинофилы) и эндотелий. Мелатонин обнаружен в тучных клетках, эндометрии, мозжечке, нейроэндокринных клетках воздухоносных путей, параганглиях, внутреннем ухе, печени, желчном пузыре, корковом слое почек. Ключевая роль гормона мелатонина определяется тем обстоятельством, что ритмам его продукции подчинены все эндогенные ритмы организма. Постоянно увеличива

APA, Harvard, Vancouver, ISO und andere Zitierweisen

24

Abdelhak, ETTAOUSSI, JAMALEDDINE Khalid, MAJD Abdessamad, et al. "Incidental Ovarian Paraganglioma in a 62-Year-Old Woman: A Case Report of Diagnostic Challenge and Surgical Management." International Journal of Health & Medical Research 04, no. 03 (2025). https://doi.org/10.58806/ijhmr.2025.v4i3n06.

Der volle Inhalt der Quelle

Annotation:

Paragangliomas are rare neuroendocrine tumors originating from chromaffin cells of the neural crest. While they typically occur in the adrenal medulla as pheochromocytomas or along the sympathetic and parasympathetic chains, paragangliomas in the female genital tract are exceptionally uncommon. This report presents a case of a large right ovarian paraganglioma in a 62-year-old woman with a medical history of hypertension and diabetes. She presented with abdominal pain and fever, which led to a diagnosis of appendicitis, though an unexpected adnexal mass was discovered during surgery. Histologi

APA, Harvard, Vancouver, ISO und andere Zitierweisen

25

Gibb, Oliver, Jacob W. Lucas, Sujay Deshpande, and Daniel C. Edwards. "Massive paraganglioma masquerading as ovarian tumor: A unique case of paraganglioma of undetermined genetic origin." Baylor University Medical Center Proceedings, January 16, 2025, 1–3. https://doi.org/10.1080/08998280.2024.2448639.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

26

Miranda, Gonzalo. "SUN-920 Familial Paraganglioma Syndrome: A Rare Case of Secondary Hypertension in Young People." Journal of the Endocrine Society 4, Supplement_1 (2020). http://dx.doi.org/10.1210/jendso/bvaa046.1865.

Der volle Inhalt der Quelle

Annotation:

Abstract Paragangliomas are rare tumors originating in the autonomic nervous system, whose clinical manifestations are the result of excessive production of catecholamines. We present a case of a 26-year-old female with 5 years of disease characterized by episodic profuse sweating, headaches and high blood pressure refractory to antihypertensive treatment. She also had intermittent palpitations which intensified 1 month before admission. Patient was cataloged with diagnosis of endocrine hypertension. She had elevated urinary fractionated metanephrines, elevated plasma normethanephrin and plasm

APA, Harvard, Vancouver, ISO und andere Zitierweisen

27

Nisa, Zaibun, Dhafir Al-Okati, Olugbenga Duroshola, and Deepali Bhatte. "Incidental bilateral ovarian paraganglioma of uterine fibroid with widespread adenomyosis: A case report." Gynecology and Obstetrics Clinical Medicine, November 2022. http://dx.doi.org/10.1016/j.gocm.2022.10.003.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

28

Al-Ward, Ruaa, Vania Balderrama Brondani, Sahar Sawani, et al. "High-Specific-Activity 131I-MIBG for the Treatment of Advanced Pheochromocytoma and Paraganglioma." Clinical Nuclear Medicine, April 17, 2024. http://dx.doi.org/10.1097/rlu.0000000000005184.

Der volle Inhalt der Quelle

Annotation:

Background Metastatic pheochromocytomas and paragangliomas (MPPGLs) are rare tumors with limited treatment options. High-specific-activity 131I-MIBG (HSA-131I-MIBG) is the only US Food and Drug Administration–approved therapy for MPPGL. We studied the efficacy and safety of HSA-131I-MIBG in routine clinical practice. Patients and Methods The primary endpoints were objective response rate (ORR) and disease control rate (DCR). Secondary endpoints were duration of response, blood pressure control, safety, overall and progression-free survival rates, MIBG uptake, and correlations with genetic back

APA, Harvard, Vancouver, ISO und andere Zitierweisen

29

Nisa, Zaibun, Dhafir Al-Okati, Olugbenga Duroshola, and Deepali Bhatte. "Corrigendum to “Incidental bilateral ovarian paraganglioma of uterine fibroid with widespread adenomyosis: A case report” [Gynecol Obstet Clin Med 2 (4) (2022) 208–210]." Gynecology and Obstetrics Clinical Medicine, February 2023. http://dx.doi.org/10.1016/j.gocm.2023.02.001.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

30

Zhou, Hong-Lu, Dan-Dan Chen, and Xiu-Ling Li. "Pan-cancer analysis identified IGF2BP2 as a potential prognostic biomarker for multiple tumor types." Egyptian Journal of Medical Human Genetics 25, no. 1 (2024). http://dx.doi.org/10.1186/s43042-023-00468-0.

Der volle Inhalt der Quelle

Annotation:

Abstract Background Insulin-like growth factor 2 (IGF2) mRNA-binding proteins 2 (IGF2BP2/IMP2), an RNA-binding protein encoded by the IGF2BP2 gene, exerts its influence across diverse pathological pathways. While accumulating evidence underscores the potential significance of IGF2BP2 in the tumorigenesis of specific cancers, a comprehensive pan-cancer investigation into its role remains absent. Methods Consequently, we conducted an exhaustive exploration employing a multitude of databases to elucidate the plausible oncogenic implications of IGF2BP2. This encompassed a comprehensive scrutiny of

APA, Harvard, Vancouver, ISO und andere Zitierweisen

31

Dravecká, Ingrid, Peter Galajda, and Marián Mokáň. "Tumour-Induced Hypoglycaemia: A Mini-review of Diagnostics and Treatment of This Rare Case of Hypoglycaemia." Bratislava Medical Journal, March 31, 2025. https://doi.org/10.1007/s44411-025-00107-7.

Der volle Inhalt der Quelle

Annotation:

Abstract Tumour-induced hypoglycaemia is one of the rare causes of hypoglycaemia. The most common causes include endogenous hypersecretion of insulin by the B cells of the islets of Langerhans themselves—Islet Cell Tumour Hypoglycaemia (ICTH). However, some tumours can lead to paraneoplastic hypoglycaemia by the production of substances interfering with glucose metabolism—Non-Islet Cell Tumour Hypoglycaemia (NICTH). NICTH usually occurs in patients with solid tumours of mesenchymal or epithelial origin, less frequently with haematological and neuroendocrine tumours. Diagnosis of tumour-induced

APA, Harvard, Vancouver, ISO und andere Zitierweisen

32

Sriram, Sanjay, Aanchal Kakkar, Chetna Sarma, et al. "Frequent Immunohistochemical Expression of Transcriptional Repressor GATA Binding 1 in Salivary Gland Neoplasms: A Sensitive but Nonspecific Marker." Archives of Pathology & Laboratory Medicine, May 27, 2024. http://dx.doi.org/10.5858/arpa.2023-0444-oa.

Der volle Inhalt der Quelle

Annotation:

Context.— Salivary gland (SG) neoplasms (SGNs) display considerable immunophenotypic diversity. A significant proportion of SG carcinomas develop metastases with increased diagnostic difficulty at metastatic sites. Transcriptional repressor GATA binding 1 (TRPS1), a novel immunohistochemical marker for breast cancer, has been found to stain certain SGNs. Objective.— To investigate TRPS1 and SRY-related HMG-box 10 (SOX10) immunoexpression in various SGNs and non-SG carcinomas, head and neck paragangliomas, and head and neck mucosal melanomas. Design.— TRPS1 immunoreactivity score (IRS) was dete

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Wir bieten Rabatte auf alle Premium-Pläne für Autoren, deren Werke in thematische Literatursammlungen aufgenommen wurden. Kontaktieren Sie uns, um einen einzigartigen Promo-Code zu erhalten!